Back to Search
Start Over
Current update of a thermosensitive liposomes composed of DPPC and Brij78.
- Source :
-
Journal of Drug Targeting . Jun/Jul2018, Vol. 26 Issue 5/6, p407-419. 13p. - Publication Year :
- 2018
-
Abstract
- Thermosensitive liposomes (TSLs) have been a prominent area of study in the discipline of tumour-targeted chemotherapeutics. The representative product of TSLs is ThermoDox® (DPPC/lyso-PC/PEG-lipid), which has advanced to Phase III clinical trials. Various groups have sought to develop a new TSL to improve upon the LTSL (lyso-lipid temperature-sensitive liposomes) formulation that is used to prepare ThermoDOX®. This review focuses on the development and recent update of an innovative TSL formulation, HaT-liposomes composed of DPPC and Brij78. Various parameters of LTSL and HaT-liposomes are compared, including size, loading efficiency, transition temperature, temperature-dependent release kinetics, stability, pharmacokinetics, biodistribution and antitumour activity. Theranostic techniques involving HaT-liposomes are reported with regard to magnetic resonance imaging of drug delivery to tumours and identification of an early therapeutic biomarker in the treated tumour. The development of a further improved TSL formulation upon HaT-liposomes with improved stability and prolonged blood circulation is reported. Delivery of membrane impermeable drugs using HaT-liposomes is explored. Finally, the challenges and future perspectives of this technology are discussed. [ABSTRACT FROM AUTHOR]
- Subjects :
- *LIPOSOMES
*NANOMEDICINE
*PHARMACOKINETICS
*DRUG delivery devices
*DRUG therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1061186X
- Volume :
- 26
- Issue :
- 5/6
- Database :
- Academic Search Index
- Journal :
- Journal of Drug Targeting
- Publication Type :
- Academic Journal
- Accession number :
- 128682063
- Full Text :
- https://doi.org/10.1080/1061186X.2017.1419361